Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Corixa Bexxar cmte. review?

Executive Summary

GlaxoSmithKline/Corixa's Bexxar (tositumomab) is slated for review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Dec. 17-18 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete response" letter (1"The Pink Sheet" May 20, In Brief). The company has said it expected a review of Bexxar before year-end (2"The Pink Sheet" Aug. 12, In Brief)...
Advertisement

Related Content

AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
Advertisement
UsernamePublicRestriction

Register

PS040728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel